Brokerages predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post $26.21 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Sangamo Therapeutics’ earnings. The lowest sales estimate is $22.20 million and the highest is $30.22 million. Sangamo Therapeutics reported sales of $21.42 million in the same quarter last year, which indicates a positive year over year growth rate of 22.4%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full-year sales of $80.43 million for the current financial year, with estimates ranging from $50.00 million to $122.91 million. For the next financial year, analysts forecast that the firm will report sales of $119.10 million, with estimates ranging from $74.18 million to $241.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.14). Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $27.21 million.

Several research firms recently commented on SGMO. ValuEngine raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 26th. BidaskClub cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 25th. Wedbush set a $10.00 price target on Sangamo Therapeutics and gave the company a “hold” rating in a report on Sunday, March 10th. Finally, Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.75.

In related news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 15,000 shares of company stock valued at $160,550 over the last quarter. 1.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of SGMO. BlackRock Inc. increased its position in Sangamo Therapeutics by 1.3% in the 4th quarter. BlackRock Inc. now owns 8,430,838 shares of the biopharmaceutical company’s stock valued at $96,785,000 after acquiring an additional 108,527 shares during the period. Wasatch Advisors Inc. boosted its position in Sangamo Therapeutics by 26.8% during the 1st quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock worth $61,418,000 after purchasing an additional 1,359,170 shares during the period. Dimensional Fund Advisors LP boosted its position in Sangamo Therapeutics by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,516,660 shares of the biopharmaceutical company’s stock worth $14,468,000 after purchasing an additional 277,550 shares during the period. BB Biotech AG purchased a new stake in Sangamo Therapeutics during the 4th quarter worth $15,498,000. Finally, Geode Capital Management LLC boosted its position in Sangamo Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 1,129,365 shares of the biopharmaceutical company’s stock worth $12,965,000 after purchasing an additional 15,750 shares during the period. Institutional investors own 54.95% of the company’s stock.

SGMO stock traded down $0.15 during mid-day trading on Friday, reaching $9.96. 46,443 shares of the company’s stock were exchanged, compared to its average volume of 1,334,101. The company has a market capitalization of $1.11 billion, a P/E ratio of -14.10 and a beta of 2.89. The company has a current ratio of 3.98, a quick ratio of 5.23 and a debt-to-equity ratio of 0.04. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $19.25.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: Quick Ratio

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.